Abstract
The kidneys are an important determinant of circulating protein levels that retain plasma proteins at the glomerular filter and reclaim filtered proteins from urine. While genetic determinants of the circulating proteome have been extensively studied, studies of the urine proteome are lacking. We performed genome-wide association studies (GWAS) of 9 million common genetic variants for each of 2,868 proteins quantified using antibody-based technology from the urine of 1,246 persons.
We identified associations between urine protein levels and at least one significant (P<1.7E-11) variant at 174 loci. Index variants were mostly (153/174) located near their encoding cis-gene and enriched for protein-altering variants. Comparative analysis with plasma levels of the respective protein revealed a shared genetic basis at 122 loci, suggesting that their levels in urine provide a readout for systemic processes. Conversely, 38 loci showed urine-specific genetic signals. Variants in CUBN and LRP2, encoding the major receptor complex for tubular protein reabsorption from renal ultrafiltrate, were associated with >20 urine proteins each and shared with urine albumin, a known CUBN ligand. Integration with molecular and clinical data suggested many functional relationships, linking genetically driven changes in urine protein levels to differential gene expression, metabolite levels, and/or risk of disease. For example, genotypes at variants in the PSCA locus were perfectly predicted by urine PSCA levels and associated with PSCA expression and diseases of PSCA-expressing tissues, including bladder cancer and urinary tract infections, demonstrating potential clinical utility of urine protein levels.
These findings are accessible through a convenient web application, and establish a comprehensive genetic framework for kidney protein handling to facilitate clinical and experimental investigations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work of S.H., O.B., N.S., M.W., and A.K. was funded by German Research Foundation (DFG) project ID 431984000 (SFB 1453). The work of N.S. and A.K. was funded by DFG project ID 499552394 (SFB 1597/1). Germany's Excellence Strategy (CIBSS, EXC-2189, project ID 390939984) supported the work of Y.L. and A.K. The work of A.K. was also supported by DFG project ID 441891347 (SFB-1479). The work of K.X. is supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant K01-DK135917. A.K. is supported by NIDDK grants R03-DK144285 and K25-DK128563. K.K. is supported by NIDDK grants R01-DK144793, R01-DK105124, R01-DK136765, and National Human Genome Research Institute (NHGRI) grants U01-HG013201 and U01-HG008680. Genotyping in the GCKD study was supported by Bayer Pharma. The GCKD study was and is supported by the BMBF (FKZ 01ER 0804, 01ER 0818, 01ER 0819, 01ER 0820 and 01ER 0821) and the KfH Foundation for Preventive Medicine. Unregistered grants to support the study were provided by corporate sponsors (listed at https://gckd.org). We are grateful for the willingness of the patients to participate in the GCKD study. The enormous effort of the study personnel of the various regional centers is highly appreciated. We thank the large number of nephrologists who provide routine care for the patients and collaborate with the GCKD study. The GCKD investigators are listed in the Supplementary Note.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committees of all participating study centers gave ethical approval for the GCKD study wich provided all patient samples and data for this study. German Clinical Trials Register number is DRKS 00003971. The study centers are: Friedrich-Alexander-University Erlangen-Nuernberg, Medical Faculty of the Rheinisch-Westfaelische Technische Hochschule Aachen, Charite University Medicine Berlin, Medical Center University of Freiburg, Medizinische Hochschule Hannover, Medical Faculty of the University of Heidelberg, Friedrich-Schiller-University Jena, Medical Faculty of the Ludwig-Maximilians-University Munich, Medical Faculty of the University of Wuerzburg.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Summary statistics for all significant gene–protein associations (pQTLs and credible sets) are available in Supplementary Tables 3, 7, and 8. The results from genetic colocalization analyses with molecular and clinical traits are provided in Supplementary Tables 10-15.
All proteo-genomic results and genome-wide summary association data are accessible through the following interactive portal: http://gwas.eu/urine-p/ (freely available after successful peer-reviewed publication) and through the NHGRI-EBI GWAS Catalog (ID will be added after publication, https://www.ebi.ac.uk/gwas/).
Detailed information on used external datasets is provided in the respective sections of the Methods.
